Articles related to GYNECOLOGICAL CANCERS

PCOS was associated with significantly elevated risk for breast, uterine, ovarian/fallopian tube, and cervical cancers in a matched cohort of more than 2.5 million women.

Long-term follow-up from the phase 3 NRG-GY018 trial showed sustained overall survival benefit for pembrolizumab plus carboplatin-paclitaxel in dMMR endometrial cancer at 48 months, while the pMMR OS advantage did not reach statistical significance despite a 9-month median improvement.

An ESMO express update to epithelial ovarian cancer guidelines added rucaparib and mirvetuximab soravtansine as treatment options, but expert commentary and two subsequent FDA approvals have raised questions about the update’s current clinical applicability.

Treatment options for platinum‑resistant ovarian cancer remain limited. New phase 3 survival data suggest that adding a novel agent to standard chemotherapy may meaningfully extend survival for this hard‑to‑treat population.

“By including FDA-approved HPV self collection tests in the guidelines, they have allowed for women to get some screening even if they do not have easy access to health care.”

Vaginal fluid collection via tampon under clinical supervision followed by bisulfite conversion and long-probe quantitative amplified signal assays for methylated DNA marker analysis.